Investigating the optimal size of anticancer nanomedicine.

@article{Tang2014InvestigatingTO,
  title={Investigating the optimal size of anticancer nanomedicine.},
  author={Li Tang and Xujuan Yang and Qian Yin and Kaimin Cai and Hua Wang and Isthier Chaudhury and Catherine Yao and Qin Zhou and Mincheol Kwon and James A. Hartman and Iwona T. Dobrucki and Lawrence W. Dobrucki and Luke B. Borst and St{\'e}phane Lezmi and William G Helferich and Andrew L. Ferguson and Timothy M Fan and Jianjun Cheng},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2014},
  volume={111 43},
  pages={15344-9}
}
Nanomedicines (NMs) offer new solutions for cancer diagnosis and therapy. However, extension of progression-free interval and overall survival time achieved by Food and Drug Administration-approved NMs remain modest. To develop next generation NMs to achieve superior anticancer activities, it is crucial to investigate and understand the correlation between the physicochemical properties of NMs (particle size in particular) and their interactions with biological systems to establish criteria for… CONTINUE READING